| References: |
Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses.
in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban.
in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily × 7 days (n = 24) or digoxin 0.25 mg twice daily × 2 days and once daily × 5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively. For the detailed information of Edoxaban, the solubility of Edoxaban in water, the solubility of Edoxaban in DMSO, the solubility of Edoxaban in PBS buffer, the animal experiment (test) of Edoxaban, the cell expriment (test) of Edoxaban, the in vivo, in vitro and clinical trial test of Edoxaban, the EC50, IC50,and affinity,of Edoxaban, For the detailed information of Edoxaban, the solubility of Edoxaban in water, the solubility of Edoxaban in DMSO, the solubility of Edoxaban in PBS buffer, the animal experiment (test) of Edoxaban, the cell expriment (test) of Edoxaban, the in vivo, in vitro and clinical trial test of Edoxaban, the EC50, IC50,and affinity,of Edoxaban, Please contact DC Chemicals. |
